Emmaus Life Sciences, Inc. (EMMA): Total Assets
$21.44M
As of 2025-12-31
$16.37M
As of 2026-06-30
-23.7%
3-year compound annual growth
-18.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.44M | -9.2% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $23.60M | -32.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $35.18M | -27.1% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $48.23M | -15.0% | 2024-07-03, Balance as of period end |
| 2021-12-31 | $56.73M | -4.7% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $59.54M | +0.1% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $59.46M | n/a | 2021-08-10, Balance as of period end |
| 2019-09-30 | $58.10M | n/a | 2021-01-25, Balance as of period end |
| 2018-12-31 | $75.28M | n/a | 2021-01-25, Balance as of period end |
| 2018-09-30 | $5.15M | -15.5% | 2018-12-11, Balance as of period end |
| 2017-09-30 | $6.10M | n/m | 2018-12-11, Balance as of period end |
| 2016-09-30 | $512.1K | -9.7% | 2017-12-29, Balance as of period end |
| 2015-09-30 | $567.1K | -57.6% | 2016-12-22, Balance as of period end |
| 2014-09-30 | $1.34M | -4.7% | 2016-01-05, Balance as of period end |
| 2013-09-30 | $1.40M | n/m | 2014-12-29, Balance as of period end |
| 2012-09-30 | $125.3K | -66.1% | 2013-12-23, Balance as of period end |
| 2011-09-30 | $370.0K | +55.8% | 2013-01-15, Balance as of period end |
| 2010-09-30 | $237.5K | n/a | 2011-12-22, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $8.52M | +160.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗